Molly Henderson
Directeur Financier/CFO chez PHATHOM PHARMACEUTICALS, INC.
Fortune : 952 533 $ au 30/04/2024
Profil
Molly Henderson is currently the CFO, Chief Accounting & Business Officer at Phathom Pharmaceuticals, Inc. She previously held positions as Chairman at Wuju Foods LLC from 2016 to 2018, Independent Non-Executive Director at Calliditas Therapeutics AB from 2020 to 2023, Corporate Controller at Ultralife Corp.
from 2000 to 2002, Manager-Audit Division at PricewaterhouseCoopers LLP, Chief Financial Officer & Executive Vice President at Advaxis, Inc. from 2018 to 2020, CFO, Secretary, Chief Business Officer & SVP at VirtualScopics, Inc. in 2013, Chief Financial & Accounting Officer at UroGen Pharma Ltd.
from 2020 to 2022, and Chief Financial Officer & Head-Investor Relations at Iovance Biotherapeutics, Inc. in 2015.
She obtained her undergraduate and graduate degrees from the State University of New York at Buffalo and also holds an MBA.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/05/2024 | 104 674 ( 0,18% ) | 952 533 $ | 30/04/2024 |
Postes actifs de Molly Henderson
| Sociétés | Poste | Début |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Directeur Financier/CFO | 05/04/2022 |
Anciens postes connus de Molly Henderson
| Sociétés | Poste | Fin |
|---|---|---|
| CALLIDITAS THERAPEUTICS AB | Directeur/Membre du Conseil | 30/05/2023 |
| UROGEN PHARMA LTD. | Directeur Financier/CFO | 25/03/2022 |
| AYALA PHARMACEUTICALS, INC. | Directeur Financier/CFO | 25/09/2020 |
| IOVANCE BIOTHERAPEUTICS, INC. | Directeur Financier/CFO | 01/08/2016 |
Formation de Molly Henderson
| State University of New York at Buffalo | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| ULTRALIFE CORPORATION | Producer Manufacturing |
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| CALLIDITAS THERAPEUTICS AB | Health Technology |
| UROGEN PHARMA LTD. | Health Technology |
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
VirtualScopics, Inc.
 VirtualScopics, Inc. Miscellaneous Commercial ServicesCommercial Services VirtualScopics, Inc. provides quantitative imaging solutions currently serving the pharmaceutical, biotechnology and medical device industries. It provides image analysis software tools and applications which are used in detecting and measuring specific anatomical structures and metabolic activity using medical images. The company's therapeutic area expertise includes oncology, rheumatoid arthritis, osteoarthritis, neurology, cardiovascular, muscle and fat measurements and COPD studies utilizing MRI, PET, CT, Ultrasound and X-Ray imaging modalities. VirtualScopics was founded by Saara Totterman, Kevin J. Parker, Jose Tamez-Pena and Edward Ashton in July 2000 and is headquartered in Rochester, NY. | Commercial Services |
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
